The value of<sup>18</sup>F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy

张迎强; 张　鑫; 王　宸

doi:10.19401/j.cnki.1007-3639.2018.07.005

您当前的位置：

首页 >

文章列表页 >

The value of¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy

更新时间：2026-01-27

- The value of¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy
- China Oncology Vol. 28, Issue 7, Pages: 505-510(2018)
- 作者机构：
  
  1. １. 中国医学科学院北京协和医学院北京协和医院核医学科,北京,100730
  2. ２. 核医学分子靶向诊疗北京市重点实验室,北京,100730
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.07.005
  CLC： R736.1
- Published Online：10 August 2018，
  
  Published：10 August 2018
- 稿件说明：
移动端阅览
张迎强,张　鑫,王　宸,等.

张迎强, 张　鑫, 王　宸. The value of¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy[J]. China Oncology, 2018, 28(7): 505-510.
张迎强,张　鑫,王　宸,等. DOI： 10.19401/j.cnki.1007-3639.2018.07.005.

张迎强, 张　鑫, 王　宸. The value of¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy[J]. China Oncology, 2018, 28(7): 505-510. DOI： 10.19401/j.cnki.1007-3639.2018.07.005.

摘要

背景与目的：碘难治性分化型甲状腺癌(radioactive iodine-refractory differentiated thyroid cancer，RAIR-DTC)是近年来研究的热点。因肿瘤细胞的异质性，不同病灶的生长速度及治疗疗效不尽相同。该研究探讨

F-FDG PET/CT在RAIR-DTC多发肺转移患者经阿帕替尼治疗效果评估中的价值。方法：纳入于中国医学科学院北京协和医学院北京协和医院经阿帕替尼治疗的RAIRDTC患者。入组患者于基线、治疗后4周及8周行CT及

F-FDG PET/CT检查。结果：共7例患者，49个肺转移灶，SUV

max

在基线时为0.8~23.2。基线时病灶的SUV

max

水平与治疗后4周及8周的SUV

max

变化（SUV

max-4w

/SUV

max-baseline

，SUV

max-8w

SUVmax-baseline

）显著相关(P0.000 1，P0.000 1)。4周及8周的病灶直径变化率(CT4w/b，CT8w/b)与基线SUV

max

无明显线性相关（P=0.666 4，P=0.478 7）。而4周的SUV

max

变化（SUV

max-4w

/SUV

max-baseline

）与CT4w/b及CT8w/b显著相关（P=0.033 3，P=0.004 8）。对于基线水平SUV

max

大于5的病灶，SUV

max-baseline

与CT4w/b、CT8w/b均具有线性关系（P=0.008 2，P=0.016 9）。结论：

F-FDG PET/CT在RAIR-DTC多发肺转移患者靶向药物治疗中具有广阔的应用前景，可以识别肿瘤一致性，辅助选取靶病灶，并通过病灶的SUVmax预测患者对靶向药物治疗的疗效。

Abstract

Background and purpose: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) is a hot topic in recent years. The growth rates of different lesions and their responses to treatment vary a lot due to the heterogeneity of tumor cells. This study aimed to explore the value of

F-FDG PET/CT in RAIR-DTC after the therapy of apatinib. Methods: RAIR-DTC patients undergoing apatinib therapy in Peking Union Medical College Hospital were enrolled.

F-FDG PET/CT was performed at baseline

4 weeks and 8 weeks after apatinib therapy. Results: A total of 7 patients including 49 lung metastases were analyzed after apatinib therapy

with SUV

max

varying from 0.8 to 23.2. The results showed that the SUV

max

level of lesions at baseline was significantly associated with the changes in SUV

max

at 4 and 8 weeks after the treatment (SUV

max-4w

/SUV

max-baseline

SUVmax-8w/SUV

max-baseline

) (P0.000 1

P0.000 1). The rate of lesion diameter change (CT4w/b

CT8w/b) was not correlated with baseline SUV

max

at 4 weeks and 8 weeks (P=0.666 4

P=0.478 7). The 4-week change in SUVmax (SUV

max-4w

/SUV

max-baseline

) was significantly associated with CT4w/b and CT8w/b (P=0.033 3

P=0.004 8). For lesions with baseline SUV

max

greater than 5

SUV

max-baseline

had a linear relationship with CT4w/b and CT8w/b (P=0.008 2

P=0.016 9). Conclusion:

F-FDG PET/CT has great value in evaluating the heterogeneity

selecting target lesions and predicting the response in patients with RAIR-DTC after apatinib therapy.

关键词

Keywords

references

Views

2127

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The research on the association between genetic alterations of DLBCLs and ¹⁸F-FDG PET/CT SUV_max and their clinical significance

Evaluation of short-term efficacy of apatinib using cervical ultrasound and thyroglobulin in the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer

Analysis of the efficacy prediction and prognostic factors for advanced gastric cancer treated with apatinib

The preliminary report about the efficacy and safety evaluation of apatinib in progressive radioactive iodine-refractory differentiated thyroid cancer within 8 weeks

¹⁸F-FDG PET/CT imaging in the monitoring of response to sorafenib in patients with radioiodinerefractory differentiated thyroid cancer

Related Author

Xiaoyan ZHOU

Chen CHEN

Tian TIAN

Ran WEI

Longlong BAO

Bingxin GU

Qunling ZHANG

Junning CAO

Related Institution

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Institute of Pathology, Fudan University

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

中国医学科学院北京协和医学院北京协和医院超声医学科

中国医学科学院北京协和医学院北京协和医院核医学科

AI问答

⁰

The value of18F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy

DOI：10.19401/j.cnki.1007-3639.2018.07.005

摘要

Abstract

关键词

Keywords

references

The value of¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy